Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07533539) titled 'Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers' on April 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Celltrion
Condition:
Type 2 Diabetes Mellitus (T2DM)
Intervention:
Drug: L03RD1
Drug: L03RD2
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: May 9, 2026
Target Sample Size: 48
Countries of Recruitment:
South Korea
To know more, visit ht...